Skip to main content

Sutro Biopharma, Inc.

STRO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001382101

No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Sutro Biopharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Sutro Biopharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Sutro Biopharma, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER12,367Sep 22, 20264
Panek James PDirector–Jun 9, 20262
Matsui ConnieDirector50,000Jun 9, 20263
Petree Daniel HDirector18,601IndirectJun 9, 20262
Lobacki Joseph MDirector–Jun 9, 20262
Jagpal SukhiDirector–Jun 9, 20262
Wigginton Jon MarcDirector–Jun 9, 20262
Dybbs MichaelDirector–Jun 9, 20262
Hunter HeidiDirector–Jun 9, 20262
Chow Gregory K.CFO4,725Jun 2, 20264
Chung JaneChief Executive Officer21,285Mar 6, 20264
Pauling DavidChief Admin. Ofcr. & GC9,748Mar 6, 20264
Leyman BarbaraChief Business Officer16,056Aug 26, 20250
Albini Edward CCFO AND SECRETARY160,805May 19, 20250
Fitzpatrick Linda ACHIEF PEOPLE & COMM. OFFICER119,744May 5, 20250
Borgman Anne ElizabethCHIEF MEDICAL OFFICER97,452May 5, 20250
Srinivasan VenkateshCHIEF TECH OP OFFICER53,686May 5, 20250
Newell William JCEO292,531Mar 7, 20250
Freund John GordonDirector–Jun 10, 20240
Vasquez NickiCHIEF PORT. STRAT & ALNCE OFCR14,279Jan 31, 20240
Shtylla BrunildaChief Business Officer0Aug 29, 20230
Hallam TrevorPres. Rsrch & Cf. Sctific Ofcr100,368Apr 17, 20230
Shabbir AnikChief Technical Ops. Officer40,827Mar 7, 20230
Sharp ShaliniDirector–Jun 8, 20220
Molina Arturo MDChief Medical Officer37,736Mar 7, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 16, 2025 (view filing)Oct 151 dayPauling DavidChief Admin. Ofcr. & GCPPurchase+12.5K$0.80+$10.0K+21.1%71.7K after
Oct 16, 2025 (view filing)Oct 151 dayGerber Hans-PeterCHIEF SCIENTIFIC OFFICERPPurchase+17.0K$0.80+$13.6K+31.0%71.8K after
Oct 16, 2025 (view filing)Oct 151 dayChung JaneChief Executive OfficerPPurchase+12.5K$0.80+$10.0K+11.3%122.8K after
Oct 16, 2025 (view filing)Oct 151 dayChow Gregory K.CFOPPurchase+19.8K$0.81+$16.0KNew position19.8K after
Oct 16, 2025 (view filing)Oct 151 dayMatsui ConnieDirectorPPurchase+50.0K$0.80+$40.0KNew position50.0K after
Jan 31, 2024 (view filing)Jan 292 daysVasquez NickiCHIEF PORT. STRAT & ALNCE OFCRSSale−12.2K$5.00−$60.9K−48.8%12.8K after10b5-1
Aug 29, 2023 (view filing)Aug 281 dayShtylla BrunildaChief Business OfficerSSale−15.4K$4.71−$72.7K−100.0%0 after
Aug 28, 2023 (view filing)Aug 253 daysShtylla BrunildaChief Business OfficerSSale−11.6K$4.59−$53.3K−47.3%12.9K after
Mar 15, 2022 (view filing)Mar 141 dayNewell William JCEOPPurchase+10.0K$7.75+$77.5K+9.4%116.5K after
Sep 28, 2021 (view filing)Sep 28Same dayVasquez NickiChief Port. Strat & Alnce OfcrSSale−3.91K$18.62−$72.7K−34.9%7.27K after